• Mashup Score: 8
    ARROW study: pralsetinib in RET fusion+ tumors - 4 year(s) ago

    Vivek Subbiah, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the ARROW study (NCT03037385), which…

    Source: VJOncology
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of weoncologists
      weoncologists

      RT @VJOncology: VIDEO: ARROW study: pralsetinib in RET fusion+ tumors w/ @VivekSubbiah of @MDAndersonNews: https://t.co/R6D69lLHoj @VJOnco…

    • Profile photo of VJOncology
      VJOncology

      VIDEO: ARROW study: pralsetinib in RET fusion+ tumors w/ @VivekSubbiah of @MDAndersonNews: https://t.co/R6D69lLHoj @VJOncology @ASCO @OncoAlert #LungCancer #ThryroidCancer #LCsm